Abstract

T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: Longitudinal Analysis during 7 Cycle Follow-up of the Rebuild Phase 2 Study

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study
Evangelos Terpos ... Meletios A Dimopoulos
Blood | VOL. 136
Evangelos Terpos, et. al.Evangelos Terpos ... Meletios A Dimopoulos
05 Nov 2020
Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World ‘Powerful’ Study
Evangelos Terpos ... Theodora Assimakopoulou
Blood | VOL. 136
Evangelos Terpos, et. al.Evangelos Terpos ... Theodora Assimakopoulou
05 Nov 2020
Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study
Efstathios Kastritis ... Meletios A Dimopoulos
Blood | VOL. 136
Efstathios Kastritis, et. al.Efstathios Kastritis ... Meletios A Dimopoulos
05 Nov 2020
Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study
Evangelos Terpos ... Meletios A Dimopoulos
Blood | VOL. 136
Evangelos Terpos, et. al.Evangelos Terpos ... Meletios A Dimopoulos
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Herpetic lymphadenitis mimicking Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma
Samuel Bidot ... Andrew L Feldman
Blood | VOL. 143
Samuel Bidot, et. al.Samuel Bidot ... Andrew L Feldman
27 Jun 2024
GM-CSF brings (good) memories
Damien Reynaud
Blood | VOL. 143
Damien ReynaudDamien Reynaud
27 Jun 2024
Introduction to a review series on oncogenic signaling and immune evasion in hematologic malignancies
Robert Zeiser
Blood | VOL. 143
Robert ZeiserRobert Zeiser
27 Jun 2024
Crespiatico I, Zaghi M, Mastini C, et al. First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. Blood. 2024;143(14):1399-1413.
-
Blood | VOL. 143
--
27 Jun 2024
View more papers